Total Payments
$99,479
2024 Payments
$4,629
Companies
17
Transactions
100
Medicare Patients
594
Medicare Billing
$132,363
Payment Breakdown by Category
Other$47,608 (47.9%)
Consulting$43,661 (43.9%)
Travel$5,794 (5.8%)
Food & Beverage$2,388 (2.4%)
Education$29.02 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,608 | 18 | 47.9% |
| Consulting Fee | $43,661 | 16 | 43.9% |
| Travel and Lodging | $5,794 | 27 | 5.8% |
| Food and Beverage | $2,388 | 37 | 2.4% |
| Education | $29.02 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $43,145 | 42 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $29,861 | 26 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,419 | 4 | $0 (2018) |
| Daiichi Sankyo Inc. | $3,083 | 2 | $0 (2024) |
| BeiGene USA, Inc. | $2,600 | 1 | $0 (2023) |
| AstraZeneca UK Limited | $2,398 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $2,125 | 2 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,920 | 1 | $0 (2018) |
| Spectrum Pharmaceuticals Inc. | $1,567 | 7 | $0 (2018) |
| Janssen Global Services, LLC | $1,500 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,629 | 6 | Daiichi Sankyo Inc. ($3,083) |
| 2023 | $2,677 | 2 | BeiGene USA, Inc. ($2,600) |
| 2022 | $7,878 | 3 | AstraZeneca Pharmaceuticals LP ($7,878) |
| 2021 | $8,930 | 5 | AstraZeneca Pharmaceuticals LP ($2,398) |
| 2019 | $17,891 | 18 | AstraZeneca Pharmaceuticals LP ($10,613) |
| 2018 | $36,407 | 42 | AstraZeneca Pharmaceuticals LP ($22,257) |
| 2017 | $21,069 | 24 | Merck Sharp & Dohme Corporation ($18,840) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $12.00 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $77.03 | General |
| 08/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,712.50 | General |
| 08/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 07/31/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,440.00 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2023 | Incyte Corporation | JAKAFI (Drug), MONJUVI, PEMAZYRE | Food and Beverage | Cash or cash equivalent | $76.97 | General |
| Category: Hematology/Oncology | ||||||
| 09/12/2023 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 11/22/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/14/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 04/25/2022 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 10/15/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 08/24/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 08/16/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 07/24/2021 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 04/26/2021 | AstraZeneca UK Limited | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,397.50 | General |
| 11/05/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $6,200.00 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $455.27 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | In-kind items and services | $181.26 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $52.96 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $37.50 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Oncology | ||||||
| 10/25/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 155 | 417 | $199,389 | $40,653 |
| 2022 | 7 | 221 | 491 | $191,720 | $48,001 |
| 2021 | 6 | 132 | 306 | $97,351 | $27,547 |
| 2020 | 5 | 86 | 184 | $63,449 | $16,162 |
Total Patients
594
Total Services
1,398
Medicare Billing
$132,363
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 70 | 264 | $140,976 | $28,629 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 41 | 92 | $33,120 | $6,606 | 19.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 24 | $8,952 | $2,236 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $11,441 | $2,150 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 20 | $4,900 | $1,031 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 66 | 219 | $94,002 | $24,848 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 43 | 101 | $31,075 | $7,543 | 24.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 31 | 65 | $23,145 | $5,236 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 37 | 37 | $20,588 | $5,156 | 25.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $10,996 | $2,426 | 22.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 16 | 32 | $7,968 | $1,790 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 21 | $3,946 | $1,002 | 25.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 25 | 85 | $25,075 | $9,686 | 38.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 114 | $40,014 | $9,345 | 23.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 17 | 17 | $11,594 | $2,702 | 23.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 46 | $11,178 | $2,624 | 23.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 30 | $6,270 | $2,391 | 38.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 14 | 14 | $3,220 | $799.82 | 24.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 32 | 86 | $30,186 | $7,244 | 24.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 13 | 42 | $12,390 | $3,699 | 29.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 33 | $8,019 | $1,928 | 24.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $7,502 | $1,792 | 23.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $5,352 | $1,499 | 28.0% |
About Dr. Patrick Ma, MD
Dr. Patrick Ma, MD is a Hematology & Oncology healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104846823.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Ma, MD has received a total of $99,479 in payments from pharmaceutical and medical device companies, with $4,629 received in 2024. These payments were reported across 100 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($47,608).
As a Medicare-enrolled provider, Ma has provided services to 594 Medicare beneficiaries, totaling 1,398 services with total Medicare billing of $132,363. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Hershey, PA
- Active Since 07/19/2006
- Last Updated 08/01/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1104846823
Products in Payments
- KEYTRUDA (Biological) $29,861
- TAGRISSO (Drug) $23,164
- IMFINZI (Drug) $17,242
- ALUNBRIG (Drug) $7,819
- IMFINZI (Biological) $2,740
- OPDIVO (Biological) $2,125
- Non-Covered $1,920
- LORBRENA (Drug) $1,452
- JAKAFI (Drug) $76.97
- LIBTAYO (Biological) $17.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Hershey
Dr. Kevin Rakszawski, M.d, M.D
Hematology & Oncology — Payments: $221,742
Hematology & Oncology $221,742
Jeffrey Pu, M.d, M.D
Hematology & Oncology — Payments: $205,003
Hematology & Oncology $205,003
Dr. Cristina Truica, M.d, M.D
Hematology & Oncology — Payments: $107,088
Hematology & Oncology $107,088
Joseph Drabick, Md, MD
Hematology & Oncology — Payments: $54,854
Hematology & Oncology $54,854
Witold Rybka, Md, MD
Hematology & Oncology — Payments: $31,971
Hematology & Oncology $31,971
Dr. Monika Joshi, Md, MD
Hematology & Oncology — Payments: $18,807
Hematology & Oncology $18,807